BGIM
BMY.RT

Boussard & Gavaudan Investment Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-492,449
Closed -$596K – 113
2020
Q4 		$596K Sell
492,449
-34,232
-6% -$72.9K 0.08% 46
2020
Q3 		$1.07M Buy
526,681
+109,888
+26% +$314K 0.14% 37
2020
Q2 		$1.42K Buy
416,793
+10,984
+3% +$39.6K 0.27% 26
2020
Q1 		$1.58M Buy
405,809
+179,689
+79% +$592K 0.34% 24
2019
Q4 		$690K Buy
+226,120
New +$588K 0.15% 22

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Boussard & Gavaudan Investment Management's BMY.RT Position: Q1 2021 in Review

Boussard & Gavaudan Investment Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 492,449 shares — an estimated $596K sold.

Boussard & Gavaudan Investment Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.58M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Boussard & Gavaudan Investment Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 492,449 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $596K.
  • Boussard & Gavaudan Investment Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Boussard & Gavaudan Investment Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.58M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q1 2021, filed 11 May 2021.